Atara Biotherapeutics reported a net loss of $4.8 million for the quarter ended June 30, 2026, compared to net income of $2.4 million in the prior year period. Cash and short-term investments totaled $9.9 million as of June 30, 2026, with a cash runway extending into mid-2027. The company held a productive Type A meeting with the FDA regarding tabelecleucel (EBVALLO), confirming the opportunity to resubmit the Biologics License Application based on the Phase 3 ALLELE trial data. Atara is eligible for a $31 million milestone payment upon FDA approval of the BLA under its agreement with Pierre Fabre Pharmaceuticals. The company operates in the biotechnology industry, developing allogeneic T-cell immunotherapies for cancer and autoimmune diseases.

Atara Biotherapeutics, Inc. announced the departure of Chief Accounting Officer Yanina Grant-Huerta, effective July 17, 2026, and the appointment of Kevin G. Sarney as interim chief financial officer, effective June 26, 206, as a consultant via Charles River CFO, Inc. Mr. Sarney will serve as the Company's principal financial officer and principal accounting officer. Atara Biotherapeutics, Inc. is a biotechnology company focused on cell therapy products.

Atara Biotherapeutics, Inc. announced the appointment of Brian Cherry to its Board of Directors as a Class I director and member of the Audit Committee, effective June 11, 2026. Mr. Cherry received an initial award of 24,000 restricted stock units vesting over three years and an annual cash retainer of $55,000. Additionally, the company held its 2026 annual meeting of stockholders on June 9, 2026, where shareholders elected AnhCo Nguyen, Ph.D. and Nachi Subramanian to the Board, approved executive compensation on an advisory basis, and authorized an amendment to the 2024 Equity Incentive Plan to increase reserved shares by 400,000. Deloitte & Touche LLP was ratified as the independent auditor. Atara Biotherapeutics is a biotechnology company focused on cell therapies.